Emine KARTAL BAYKAN, Nazlıgül KARAÜZÜM YALÇIN, Ünsal AYDIN, Şenay DURMAZ, Ahmet Veli ŞANİBAŞ, İdris BAYDAR, Aykut TURHAN, Ayşe ÇARLIOĞLU

Prolaktinoma Tanılı Hastalarda Prediyabet Sıklığı

Amaç: Prolaktinin (PRL) çeşitli hayvan türlerinde glikoz intoleransı, hiperinsülinemi ve insülin direncini indüklediği daha önce yapılan çalışmalarda gösterilmiştir. Biz bu çalışmada prolaktinoma tanılı hastalarda metabolik etkilere yönelik daha fazla bilgi edinmeyi ve prediyabet sıklığını göstermeyi amaçladık. Yöntemler: Çalışmamıza kliniğimizde takip ettiğimiz bilinen kronik hastalığı olmayan 30 prolaktinoma tanılı hasta ve kontrol grubu olarak benzer yaş, cinsiyet ve vücut kitle indeksi (VKİ)’ne sahip 66 sağlıklı insan dahil edildi. Antropometrik parametreler (boy, kilo, VKİ) ve serum hbA1c, açlık kan plazma glukozu(APG), PRL değerleri ölçüldü. Bulgular: Prolaktinomalı hastalarda prediyabet anlamlı bir şekilde yüksek bulundu. Prolaktinoma ile APG arasında pozitif koreleasyon saptandı. Prolakinoma ile VKİ arasında pozitif koreleasyon saptandı. Sonuç: Prolaktinomalı hastalarda prediyabet sıklığında artış saptandı. Prolaktinoma ile APG yüksekliği ve VKİ’ndeki artış anlamlı bir şekilde ilişkiliydi.

Prediabetes Frequency in Patients With Prolaktinoma

Objective: Objective: Studies have shown that prolactin (PRL) induces glucose intolerance, hyperinsulinemia and insulin resistance in various animal species. In this study, we aimed to get more information about the metabolic effects of prolactinoma in patients diagnosed with prolactinoma and to show the frequency of prediabetes in these patients. Methods: The study included 30 patients with prolactinoma without any chronic disease in our clinic and 66 healthy people with similar age, gender and body mass index (BMI) as the control group. Anthropometric parameters (height, weight, BMI), serum HBA1c, fasting blood plasma glucose (FPG) and PRL values were measured. Results: Prediabetes was significantly higher in patients with prolactinoma. There was a positive correlation between prolactinoma and FPG. and BMI. A positive correlation was found between prolactinoma and BMI. Conclusion: An increased frequency of prediabetes was detected in patients with prolactinomas. Prolactinoma was significantly associated with increased FPG and increased BMI.

PDF

___

1. Biller B, Luciano A, Crosignani P, et al.: Guidelines for the diagnosis and treatment of hyperprolactinemia. The Journal of reproductive medicine 1999; 44 (12 Suppl): 1075-84.
2. Mindermann T, Wilson CB: Age‐related and gender‐related occurrence of pituitary adenomas. Clinical Endocrinology 1994; 41: 359-64.
3. Nomikos P, Buchfelder M, Fahlbusch R: Current management of prolactinomas. Journal of neuro-oncology 2001; 54: 139-50.
4. Fernandez A, Karavitaki N, Wass JA: Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK). Clinical endocrinology 2010; 72: 377-82.
5. Daly AF, Rixhon M, Adam C, et al.: High prevalence of pituitary adenomas: a crosssectional study in the province of Liege, Belgium. The Journal of Clinical Endocrinology & Metabolism 2006; 91: 4769-75.
6. Daly AF, Tichomirowa MA, Beckers A: The epidemiology and genetics of pituitary adenomas. Best practice & research Clinical endocrinology & metabolism 2009; 23: 543-54.
7. Association AD: Diagnosis and classification of diabetes mellitus. Diabetes care 2014; 37 (Supplement 1): S81-S90.
8. Ferrannini E, Gastaldelli A, Iozzo P: Pathophysiology of prediabetes. Medical Clinics 2011; 95: 327-339.
9. Association AD: Executive summary: Standards of medical care in diabetes--2014. Diabetes care 2014; 37:S5.
10. Doknic M, Pekic S, Zarkovic M, et al: Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. European journal of endocrinology 2002; 147: 77-84.
11. Shibli-Rahhal A, Schlechte J: The effects of hyperprolactinemia on bone and fat. Pituitary 2009; 12: 96-104.
12. Serri O, Beauregard H, Rasio E, Hardy J: Decreased sensitivity to insulin in women with microprolactinomas. Fertility and sterility 1986; 45: 572-4.
13. Park S, Kim DS, Daily JW, Kim SH: Serum prolactin concentrations determine whether they improve or impair β‐cell function and insulin sensitivity in diabetic rats. Diabetes/metabolism research and reviews 2011; 27: 564-74.
14. Glasow A, Breidert M, Haidan A, et al: Functional aspects of the effect of prolactin (PRL) on adrenal steroidogenesis and distribution of the PRL receptor in the human adrenal gland. The Journal of Clinical Endocrinology & Metabolism 1996; 81: 3103- 11.
15. Pala NA, Laway BA, Misgar RA, Dar RA: Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline. Diabetology & metabolic syndrome 2015; 7: 99.
16. Asai-Sato M, Okamoto M, Endo M, et al: Hypoadiponectinemia in lean lactating women: Prolactin inhibits adiponectin secretion from human adipocytes. Endocrine journal 2006; 53: 555-62.
17. Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S: Insulin sensitivity and hyperprolactinemia. Journal of endocrinological investigation 2003; 26: 341-6.
18. Pelkonen R, Nıkkılä EA, Grahne B: Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clinical endocrinology 1982; 16: 383-90.
19. Yavuz D, Deyneli O, Akpinar I, et al: Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. European Journal of Endocrinology 2003; 149: 187-94.
20. Santos‐Silva CM, Barbosa FR, Lima GA, et al: BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity 2011; 19: 800-5.
21. Naliato EC, Violante AH, Caldas D, et al: Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clinical endocrinology 2007; 67: 845-52.
22. Ling C, Svensson L, Odén B, et al: Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. The Journal of Clinical Endocrinology & Metabolism 2003; 88: 1804-8.
23. Moore BJ, Gerardo-Gettens T, Horwitz BA, Stern JS: Hyperprolactinemia stimulates food intake in the female rat. Brain research bulletin 1986; 17: 563-9.
24. Goede D, Hauser R: Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss medical weekly 2006; 136 (1516).
25. Creemers L, Zelissen P, Van't Verlaat J, Koppeschaar H: Prolactinoma and body weight: a retrospective study. European Journal of Endocrinology 1991; 125: 392-6.
26. Greenman Y, Tordjman K, Stern N: Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clinical endocrinology 1998; 48: 547-53.
27. Berinder K, Nyström T, Höybye C, Hall K, Hulting A-L: Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 2011; 14: 199-207.
28. Landgraf R, Landgraf-Leurs M, Weissmann A, et al.: Prolactin: a diabetogenic hormone. Diabetologia 1977; 13: 99-104.